Follow us on Facebook  Follow us on Twitter  Investors Hub Board
Wall Street Newscast  Where Wall Street Listens

Join Our Email List
Email:  

Home | Email Alerts | Message Board | Twitter | Awareness Services | Contact
stock picks



Intellicell Biosciences, Inc (OTC:SVFC)
460 Park Avenue
New York, NY 10022
Phone: 646-576-8700
Email: info@southstreetmedia.com 
Real-Time Quote

SVFC Updates

SVFC Message Board


Interview with Dr. Victor, the Chairman and CEO of SVFC - July 11, 2013


About Intellicell Biosciences, Inc.

IntelliCell™ is pioneering a new proprietary medical process that results in acquiring Vascular Fraction Cells (VFC), also known as stromal vascular fraction. VFC cells are known to contain significant numbers of various cell types including adult stem cells, endothelial cells, fibroblast cells, red blood cells, and much more. The Company has developed a novel ultrasound process to assist the laboratory in the preparation of the VFC cells. In a process similar to the acquisition of autologous stem cells from bone marrow aspirate, the IntelliCell VFC cells are being given to physicians working in the field of regenerative medicine. www.intellicellbiosciences.com


Shares Authorized: UR Public Float: UR
Shares Outstanding: 120 million Price Target: $0.10

* based on OTC Markets data


SVFC Trading at Market Cap of only $740,000
La
st Updated: Oct. 29, 2013 -12:40pm EST

(NEW YORK)--Intellicell Biosciences, Inc. (OTC:SVFC) draws in retail trader interest as stock trades at a market capitalization of only $740,000.

WSNC has confirmed that as of Oct. 29, 2013, the Company had approximately 185 million common shares issued and outstanding, thus giving the stock a current market cap of just around $740,000 at a price of $0.004 per share.

Obviously the company has been in the process of converting shares as they proceed in wipe away the last of their debt from their balance sheet. From our understanding, there still may be a few hundred thousand left to clear off the balance sheet before conversions may be over, but with the stock trading sometimes on average $25,000 to $50,000+ per day in retail volume the completion of this debt clearance may not be too far off.

In addition, the Company is currently in negotiation on substantial financing that would cover all of the company costs for full implementation for their stem cell facilities in NYC, and to other hospitals. The main aspect in this potential institution investment is that this potential large financing would reduce any need for future equity debt, and its expected to be on a much less toxic bases as this would be structured as a long-term capital infusion.

Ludlow Research Highlights 

- Unique Stem Cell Extraction Technology from Blood Vessels
- FDA Registered Facility in NYC
- One of few cGTP Cell Manufacturing Facilities in US
- Use of Ultrasonic Cavitation instead of Enzymes
- Patent for Stem Cell Extraction Process
- Appointment of
Dr Zain Khalpey to Advisory Board

FDA Compliant Stem Cell Facility

In November 2012, the Company was notified according to the Federal Drug Administration (“FDA”) validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P’s), such as the IntelliCell autologous stromal vascular fraction cellular product. 

IntelliCell's proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation. This technology is an innovative mechanical method for the separation of stromal vascular fraction without the use of enzymes. Ultrasonic cavitation is an innovative mechanical method of separating SVFCs from fat tissue. Vascular cells derived by IntelliCell's proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures.





Safe Harbor Statements:

This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Disclaimer
:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast ("WSNC") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated fifteen thousand dollars for ongoing research and media services. WSNC has yet to receive any payment per agreement executed April 2013 as of the date of this disclosure. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.

Your use of this website is subject to our terms & conditions. © Wall Street Newscast 1998 - 2011

This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the
expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements
are subject to risks and uncertainties that could cause actual results to differ materially from those projected.